Primary ependymoma of the ovary, in which long-term oral etoposide (VP-16) was effective in prolonging disease-free survival.

Abstract

BACKGROUND:

Ovarian ependymoma is an extremely unusual teratoma of the ovary with only eight cases previously reported in the literature worldwide.

CASE:

A 26-year-old woman presented in 1992 with a sensation of abdominal fullness. The laparotomy revealed ovarian cancer (stage III), which proved to be an ependymoma pathologically. Three courses of the PVP regimen (cisplatin, vinblastine, peplomycin) and pelvic irradiation were administered postoperatively. Oral administration of etoposide (VP-16) was initiated after the residual tumor began to proliferate, and the tumor decreased in size and never regrew during etoposide administration for a total of 5 years and 8 months. The recurrent tumor was observed soon after the drug was discontinued.

CONCLUSION:

Oral administration of etoposide was effective in prolonging disease-free survival.

• Authors: M Mikami, Y Komuro, N Sakaiya, C Tei, T Kurahashi, S Komiyama, T Hirose
• Journal: Gynecologic oncology (Gynecol Oncol) Vol. 83 Issue 1 Pg. 149-52 (Oct 2001) ISSN: 0090-8258 [Print] United States
• PMID: 11585429 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright 2001 Academic Press.

Chemical References

• Antineoplastic Agents, Phytogenic
• Etoposide

Topics

• Administration, Oral
• Adult
• Antineoplastic Agents, Phytogenic (therapeutic use)
• Combined Modality Therapy
• Disease-Free Survival
• Ependymoma (drug therapy, pathology, radiotherapy, surgery)
• Etoposide (therapeutic use)
• Female
• Humans
• Ovarian Neoplasms (drug therapy, pathology, radiotherapy, surgery)